ABBV241213P202500
- 0.00
- 0.000.00%
AbbVie Newsroom
Unlearn's 2024 Achievements Drive Innovation in AI for Clinical Development
Express News | Hungary's Richter CEO Says Previous Pace of Growth in Dividend Payouts Cannot Be Maintained
Express News | Hungary's Richter CEO Says Company Eyeing Acquisition Targets for Next Year
Express News | Hungary's Richter CEO Expects Slowdown in Sales Growth for Vraylar in 2025
Why AbbVie Inc. (ABBV) Is the Best Safe Stock to Buy According to Analysts?
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
Press Release: AbbVie Completes Acquisition of Aliada Therapeutics
AbbVie Completes Acquisition Of Aliada Therapeutics >ABBV
BofA Securities Maintains AbbVie(ABBV.US) With Hold Rating, Announces Target Price $191
AbbVie Completes Acquisition of Aliada Therapeutics
AbbVie (ABBV.US) JAK inhibitor "upadacitinib" is proposed for priority review in China.
On December 10, the official website of the Center for Drug Evaluation (CDE) of China's National Medical Products Administration announced that AbbVie (ABBV.US) has applied for the inclusion of upadacitinib sustained-release tablets in priority review, with the intended indication being the treatment of adult giant cell arteritis (GCA).
BofA Restarts Coverage of 11 Large-cap Biopharmas
Market Falls Wednesday, but Googles Chip Impresses | WST
AbbVie Treatment of Multiple Myeloma Granted FDA Orphan Designation
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Analyst Scoreboard: 19 Ratings For AbbVie
B of A Securities Reinstates Neutral on AbbVie, Announces $191 Price Target
AbbVie Analyst Ratings
Citi Maintains AbbVie(ABBV.US) With Buy Rating
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Protagonist Therapeutics (PTGX)